Dear colleagues I have the following questions concerning the safety of mRNA vaccines targeting the spike protein of SARS-Cov2:
1) The vaccine elicits antibodies which block the peptide domain used by the S-protein to dock on the cytoplasmic membrane angiotensin ACE-2 receptor.
Do you have any research work done that proves that the vaccine elicited antibodies do not cross-react with the angiotensin peptide domain(s) and thus blocking it also? If such possibility exists, even at minimal level, the consequences would be very serious given the extensive role of angiotensin-II in our physiology
2) The incorporation of ribonucleotides in RNA synthesis is only done on the 3’ carbon in nature. However, chemically it is also possible to use the 2’ carbon. Since the mRNA vaccine is synthetic:
a) Does the mRNA vaccine include only mRNA molecules that are elongated on the 3’ carbon? b) What was done to avoid elongation on the 2’ carbon or to get red of it if the vaccine was produced as a mixture?
c) The mRNA is degraded post translation. Are our cells capable of degrading an mRNA that was synthesized using the 2’ carbon that do not exist in nature in live systems.
Abdel H. Labidi, MD, PhD
A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups.
Dear A. Labidi
It is indeed an upsetting matter. We all want this to stop and of course to stop the collapse of hospitals and care centres.
I above all I would like to ask a question about the new strains. Maybe with a second thought might reduce the trouble to the least expected,maybe even reduce the question to its simplest form but I would still try.
Would anyone say the sequencing of the conserved domains of the protein (whether about the new strains or not or at least crowd the majority of the strains) would you be able to fullfil the needs in vaccine requirements? Maybe say a% of error, maybe not all strains at the same time, but maybe then suggest it is not vital for the virus... I don't want to be simplistic, but the little research I have done, there is a possibility the spike protein S can escape certain features imposed and the first one is what is causing this letality. There is also a way for the virus to get in even if you try to stop it...
Another question I would like to ask is about the properties of the mRNA. It is best suited as monocatenary however, if you could change it to cDNA by a "Taq polymerase" to make It loose its properties. Maybe it would not invade. Either by infection or the PCR test they make.
Could you be positive if you receive the mRNA vaccine maybe confusing its effects? Surely you will have to notify it...
Thank you
Mª Angeles Zorrilla Lopez-Perea
Thank you very much for your thoughtful response. Time will tell.....
A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups.
Anaphylactic reactions with Pfizer and Moderna m-RNA COVID-19 vaccines (1)
After a total of 9943 247 doses of the Pfizer-BioNTech vaccine and 7581 429 doses of the Moderna vaccine reportedly administered in the United States, 47 and 19 cases of anaphylactic reactions with Pfizer-BioNTech and Moderna COVID-19 vaccines respectively have been reported in this JAMA article.
1. Article Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccin...
Dear Dr. Yousuf:
Thank you for your reply.
I am aware of the publication you mentioned. These articles are descriptive of the facts after they happened.
My question is slightly different. I am asking if there is any basic research done to show that there are no homologies between SARS-Cov2 proteins and human proteins?
I refer you to my second more complete posting on ResearchGate entitled “
The safety of vaccines targeting SARS-Cov2 proteins
I have suggested which experiments should be done to clearly answer the questions.
The same goes for the synthetic mRNA questions, I would appreciate your comments…
So, did you see any research with the proposed experiments done?
- Badges
- Science topic
- Similar topics
- Medicine
- Disease
- Infectious Diseases
- Immunization
- Vaccination
- Vaccines